Q3 2021 - Deal Volumes Moderate as Terms Continue to Favor Companies

Q&A with Merritt Hummer of Bain Capital Ventures



On valuations and later-stage investments: "As a growth investor, I believe the valuation environment puts a bigger onus on us to make the right calls on investments. ... We have to make sure we are picking winners

who will grow into and beyond their valuations."


On the Bain Capital Ventures platform: "Everyone on the Bain Capital Ventures team is laser-focused on one or two sectors. ... Because we spend a lot of time in our areas, we like to think we can disproportionately support and contribute to the success of our portfolio companies."

On embedded marketplaces: "We believe that the future of vertical SaaS will be defined by embedded financial services and embedded marketplaces. ... We are seeing embedded marketplaces pop up everywhere – in software for construction, spas and salons, restaurants, financial institutions ... the list goes on."


Read the full interview on Cooley GO. cooleygo.com

The third quarter of 2021 continued to support a strong financing environment, as we have witnessed throughout the year. In Q3, Cooley handled 339 disclosable deals representing more than \$18.1 billion of invested capital. While slightly lower than recent prior quarters, this is still robust compared to historical trends. Median pre-money valuations remained strong during the quarter, and we saw significant valuation increases in Series A and B rounds. Of note, 47% of transactions had a median pre-money valuation greater than \$100 million. Similarly, the percentage of transactions that were up rounds reached another notable level, as 97% of transactions during the quarter were up rounds.


Amount Raised



Deal Volume



Median Pre-Money Valuation



For more venture financing trends, view our interactive data visualization on Cooley GO: cooleygo.com/trends Deal terms in Q3 continued a company-friendly trend, as we have seen throughout the year. For example, only about 3% of transactions involved the sale of fully participating preferred stock, the percentage of transactions that included a recapitalization declined, and a smaller percentage of our life sciences deals included tranching. Q3 did show a slight uptick in the utilization of pay-to-play provisions – but even with that increase, only approximately 3% of our disclosable deals incorporated those structures.


According to PitchBook's Q3 2021 Global League Tables, we advised clients on more company-side VC deals – in the US and globally – and US venture capital deals than any other law firm. To stay up to date on the latest industry insights and founder resources, visit Cooley GO.

Spotlight on life sciences


After a surge in deal volumes in Q2, Cooley handled 61 disclosable life sciences-focused deals in Q3 2021, representing more than \$3.5 billion of invested capital. Though deal volume was down relative to Q3 2020, the dollars raised represented a 25% increase relative to the same quarter of 2020. Of note, the percentage of life sciences deals structured in tranches decreased to just over 8% of transactions in Q3. This represented a marked decrease from prior quarters, which may be a sign of investor optimism in the sector. To view more details on life sciences trends, use the "Life sciences" filter in our interactive data visualization tool. cooleygo.com/trends

Spotlight on tech


In a continuation of robust trends seen throughout the year, Cooley handled 195 disclosable technology sector deals in Q3 2021, representing more than \$9.9 billion of invested capital. Deal volume was more than 19% higher relative to Q3 2020. Aggregate dollars raised in Q3 2021 increased 77% relative to Q3 2020. To view more details on technology deal trends, use the "Technology" filter in our interactive data visualization tool. cooleygo.com/trends









Up, Down and Flat Rounds




Pay-to-Play



Recapitalization



Liquidation Preference: Participation Features



About the Cooley Venture Financing Report

This report provides data reflecting Cooley's experience in venture capital financing terms and trends. Information is taken from a subset of the transactions in which Cooley served as counsel to either the issuing company or investors. For more information regarding this report, please contact one of our Cooley lawyers.

About Cooley

Cooley's lawyers solve legal issues for entrepreneurs, investors, financial institutions and established companies. Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and bet-the-company litigation, where innovation meets the law.

cooley.com

Practice co-chairs

Matthew Bartus		+65 6962 7511
Peter Werner	+1 415 693 2172	
Beijing	Xun Zeng	+86 10 8540 0668
Boston	Giselle Rivers	+1 617 937 2378
Chicago	Laurie Bauer	+1 312 881 6600
Colorado	Mike Nelson	+1 720 566 4021
Hong Kong	Henry Yin	+852 3758 1216
London	Tom Goodman	+44 (0) 20 7556 4391
Los Angeles	Steven Dunst	+1 310 883 6419
New York	Sacha Ross	+1 212 479 6702
Palo Alto	Lauren Creel	+1 650 843 5068
Reston	Mike Lincoln	+1 703 456 8022
San Diego	Karen Deschaine	+1 858 550 6088
San Francisco	Daniel Paramés	+1 415 693 2044
Seattle	Sonya Erickson	+1 206 452 8753
Shanghai	Andrew Harline	+86 21 6030 0618
Singapore	Ferish Patel	+65 6962 7510

Washington, DC+1 202 728 7115

This Cooley Venture Financing Report is not intended to provide specific legal advice or to establish an attorney-client relationship. Copyright © 2021 Cooley LLP, 3175 Hanover Street, Palo Alto, CA 94304; Cooley (UK) LLP, 22 Bishopsgate, London, UK EC2N 4BQ, UK. Permission is granted to make and redistribute, without charge, copies of this entire document provided that such copies are complete and unaltered and identify Cooley LLP as the author. All other rights reserved.